Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3,100 new brands collectively earned Rs 1,097 crore, with significant ...

The results go a long way to firming up sentiment about Enhertu, which had been widely tipped to become a multibillion-dollar brand before the ILD issue dulled some of its lustre. Much of that ...

AstraZeneca’s Enhertu (trastuzumab deruxtecan) led the market among new drugs, followed by Sun Pharma, which generated Rs 50 crore from 18 brands, and Dr. Reddy’s, which recorded Rs 45 crore ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical ...

Demandbase, the pioneer in account-based GTM for B2B enterprises, today announces it has been named a Leader in "The Forrester Wavetm: Intent Data Providers For B2B, Q1 2025." The Forrester report ...

Binary Defense, the trusted leader in Managed Detection and Response (MDR), has been recognized as a Strong Performer in The Forrester Wavetm: Managed Detection And Response Services, Q1 2025. The ...

Astellas refiled its marketing application in May, and the FDA gave it a six-month priority review, reflecting its status as the first drug targeting a brand ... 3 trial of Enhertu in advanced ...